MYO shares were down nearly 45% to $6.46 apiece by the afternoon.
The company — maker of the MyoPro upper limb orthosis — is selling more than 2.1 million shares at $7 apiece, raising about 15 million before underwriting discounts and commissions and offering expenses payable by the company.
On top of the public offering, Myomo is offering investor warrants to purchase up to an aggregate of 2,143,000 shares of common stock at the exercise price of $7.50 per share over the next five years.
Roth Capital Partners is the sole book-running manager for the offering, with Dougherty & Co. acting as co-manager.
Myomo stock has had a wild ride over the past week, with company management going as far as to say that it was unaware of any business development that warranted the trading volatility.
The Cambridge, Mass.–based company on Jan. 30 enacted a 1-for-30 reverse stock split. It announced last week that it expects fourth-quarter revenue in the $1.4–1.5 million range and full-year 2019 revenue in the $3.7–3.8 million range. Wall Street analysts on average have predicted $1.09 million in Q4 revenue and $3.41 million in full-year revenue.